Jinhui Zhang

Jinhui Zhang

Auto-generated profile, based on publicly available information

Jinhui Zhang

Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SYShuai Yuan
Shuai Yuan
SHShao-Hua He
Shao-Hua He
LLLu-Yao Li
Lu-Yao Li
SXShu Xi
Shu Xi
HWHong Weng
Hong Weng
XZXian-Tao Zeng
Xian-Tao Zeng
SLC12A5, a neuron-specific potassium-chloride co-transporter, has been reported to promote tumor progression, however, the underlying mechanism remains unclear. Here we report that SLC12A5 functions as an oncogene to promote tumor progression and castration resistance of prostate cancer through the N6-methyladenosine (m6A) reader YTHDC1 and the transcription factor HOXB13. We have shown that the level of SLC12A5 was increased in prostate cancer, in comparison to its normal counterparts, and further elevated in castration-resistant prostate cancer (CRPC). The enhanced expression of SLC12A5 mRNA was associated with neuroendocrine prostate cancer (NEPC) progression and poor survival in prostate cancer. Furthermore, we demonstrated that SLC12A5 promoted the castration resistance development of prostate cancer in addition to the cell proliferation and migration. Interestingly, SLC12A5 was detected in the cell nucleus and formed a complex with nuclear m6A reader YTHDC1, which in turn upregulated HOXB13 to promote the prostate cancer progression. Therefore, our findings reveal a mechanism that how the potassium-chloride cotransporter SLC12A5 promotes the tumor progression and provide a therapeutic opportunity for prostate cancer to apply the neurological disorder drug SLC12A5 inhibitors.

9 December 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JZJinhui Zhang
Jinhui Zhang
SSSusan Daniela Selaya
Susan Daniela Selaya
DSDiaa Shakleya
Diaa Shakleya
AMAdil Mohammad
Adil Mohammad
PFPatrick J. Faustino
Patrick J. Faustino

1 December 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YYYang Yang
Yang Yang
AAAnn-Marie Ako-Adounvo
Ann-Marie Ako-Adounvo
JWJiang Wang
Jiang Wang
JZJinhui Zhang
Jinhui Zhang
DWDaniel Willett
Daniel Willett
MAMuhammad Ashraf
Muhammad Ashraf

5 August 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JZJinhui Zhang
Jinhui Zhang
RRRamesh Raghavachari
Ramesh Raghavachari
DKDouglas C. Kirkpatrick
Douglas C. Kirkpatrick
DKDavid A. Keire
David A. Keire
XXXiaoming Xu
Xiaoming Xu
PFPatrick J. Faustino
Patrick J. Faustino

17 February 2022 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Open access
PDF file
JZJinhui Zhang
Jinhui Zhang
YYYang Yang
Yang Yang
MAMuhammad Ashraf
Muhammad Ashraf
CCCelia N. Cruz
Celia N. Cruz
SLSau Lee
Sau Lee
PFPatrick J. Faustino
Patrick J. Faustino
Rationale: Systemic absorption of UV‐filtering chemicals following topical application of sunscreens may present a safety concern. The Food and Drug Administration (FDA) had recommended an in vitro skin permeation test (IVPT) to evaluate the potential of this safety risk for the evaluation of sunscreens prior to clinical studies. Therefore, a sensitive and robust bioanalytical method(s) were required for IVPT studies of different topical sunscreen products. Methods: An analytical procedure to quantitate sunscreen UV‐filtering components and excipients in IVPT samples including avobenzone, octocrylene, oxybenzone, ecamsule, methylparaben and propylparaben was developed employing a RapidFire 360 robotic sample delivery system coupled with a triple quadrupole mass spectrometer. The analytical procedure was developed and validated according to the requirements of the FDA Bioanalytical Method Validation Guidance for Industry (2018). Results: The analytical method provided a turnaround time of 12 seconds per sample and was determined to be accurate, precise, specific, and linear over the corresponding analytical ranges. The validated method was successfully applied for two IVPT studies for evaluating the skin permeation potential of UV‐filtering chemicals and assisting with the selection of the sunscreen products for the clinical study conducted by the FDA. Conclusions: This work highlights the first analytical procedure that has applied a non‐chromatographic‐MS/MS automation platform to an in vitro biopharmaceutics study. The analytical platform simultaneously quantitated four UV filters and two excipients in complex media to evaluate their permeation in IVPT studies. The sample throughput and analytical performance of advanced automation platforms indicate their analytical procedure has the potential to significantly advance the efficiency of IVPT studies to evaluate permeation of a wide variety of UV chemical filters and excipients for topical OTC sunscreen products.